Related Experiment Video
Updated: May 1, 2026

06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
10.8K
[EPCA-2 in the early diagnosis of prostate cancer]
1Department of Urology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, China. ydsxinyi@163.com
Zhonghua Nan Ke Xue = National Journal of Andrology
|July 9, 2010
Abstract:
More and more clinical evidence has confirmed the limitations of the use of serum PSA in the screening, detection and treatment of prostate cancer, and scientists are continuously seeking for new biomarkers of the disease. The discovery of early prostate cancer antigen 2 (EPCA-2) has provided a new base for the screening, detection, treatment and follow-up of prostate cancer.

